Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More People Than Previously Believed Have Schizophrenia.

2.

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

3.

Increased detection of adenomas may reduce colon cancer risk after colonoscopy in FIT-based screening.

4.

Including Bereavement in the Care Continuum.

5.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot